X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Under the collaboration with Targovax, Agenus will supply QS-21 STIMULON and scientific support for up to three initial TG01 clinical trials in different cancer indications.
Lead Product(s): Apricoxib,Stimulon
Therapeutic Area: Oncology Product Name: TG01
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Agenus
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 07, 2022
Details:
With the support from Innovation Norway, Targovax has move the TG program forward faster and more broadly, and thus bring benefit to a patient group with poor prognosis and few available treatment options.
Lead Product(s): Apricoxib,Gemcitabine
Therapeutic Area: Oncology Product Name: TG01
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Innovation Norway
Deal Size: $0.9 million Upfront Cash: Undisclosed
Deal Type: Funding January 12, 2022
Details:
Targovax has granted an extension of 3 months to the exclusive option agreement with IOVaxis Therapeutics of Nantong, China, for clinical development and licensing of the Targovax mutant RAS vaccines TG01 and TG02 in China, Hong Kong, Macau and Singapore.
Lead Product(s): Apricoxib
Therapeutic Area: Oncology Product Name: TG01
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: IOVaxis Therapeutics
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 06, 2021
Details:
Under the agreement, IOVaxis and Targovax will jointly define a development plan in the territory, and IOVaxis will be responsible for all local regulatory filings and will sponsor clinical trials.
Lead Product(s): Apricoxib
Therapeutic Area: Oncology Product Name: TG01
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: IOVaxis Therapeutics
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
